Saturday 17 October 2026
Export IBIO’s income statement to Excel — free account
iBio, Inc.
IBIO Healthcare Biotechnology
In the quarter to June 2026, revenue grew 100.0%, EPS grew 77.4% and free cash flow fell 35.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.77
0.01
−1.28%
Follow IBIO
iBio, Inc. (IBIO) P/E ratio
iBio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 3.6× (March 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Dec 2024 | 1.4× | — |
| Jun 2024 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.6×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. | n/m |
| ACET Adicet Bio, Inc. compare | n/m |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| CLNN Clene Inc. compare | n/m |
| HYPD Hyperion DeFi, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)